Clinical study on the efficacy of O-(beta-hydroxyethyl)rutoside (HR) in varicosis of pregnancy.
In a double-blind trial involving 69 patients, the effect of O-(beta-hydroxyethyl) rutoside (HR)* in the treatment of varicosis of pregnancy has been investigated. The number of patients subjectively improving in the active drug group was significantly greater than in the placebo group; patients receiving HR also showed a small but significant decrease in leg circumference. Throughout the eight-week period of the trial, there were only minimal side-effects and healthy babies were delivered with good Apgar-scores.
D000328:Adult; D005260:Female; D006801:Humans; D006896:Hydroxyethylrutoside / Q000627:therapeutic use*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D014648:Varicose Veins / Q000188:drug therapy* / Q000209:etiology
D006896:Hydroxyethylrutoside